You are here » Home » Companies » Company Overview » Arihant Multi Commercial Ltd

Arihant Multi Commercial Ltd.

BSE: 506113 Sector: Others
NSE: N.A. ISIN Code: INE776N01028
BSE LIVE 15:45 | 27 Aug Stock Is Not Traded.
NSE LIVE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 134.40
PREVIOUS CLOSE 167.90
VOLUME 1774
52-Week high 134.40
52-Week low 0.00
P/E 13440.00
Mkt Cap.(Rs cr) 486.53
Buy Price 0.00
Buy Qty 0.00
Sell Price 134.40
Sell Qty 66601.00
OPEN 134.40
CLOSE 167.90
VOLUME 1774
52-Week high 134.40
52-Week low 0.00
P/E 13440.00
Mkt Cap.(Rs cr) 486.53
Buy Price 0.00
Buy Qty 0.00
Sell Price 134.40
Sell Qty 66601.00

Arihant Multi Commercial Ltd. (ARIHANTMULTI) - Chairman Speech

Company chairman speech

CHAIRMAN AND MANAGING DIRECTOR

As required by Clause 49 of Listing Agreement the Managing Director and CEO’sDeclaration for Code of Conduct is given below:

To

The Members of

Lifeline Drugs and Pharma Limited

(a) We have reviewed financial statements and the cash flow statement for the year andthat to the best of our knowledge and belief:

(i) these statements do not contain any materially untrue statement or omit anymaterial fact or contain statements that might be misleading;

(ii) these statements together present a true and fair view of the company’saffairs and are in compliance with existing accounting standards applicable laws andregulations.

(b) There are to the best of our knowledge and belief no transactions entered into bythe company during the year which are fraudulent illegal or violative of thecompany’s code of conduct.

(c) We accept responsibility for establishing and maintaining internal controls forfinancial reporting and that we have evaluated the effectiveness of internal controlsystems of the company pertaining to financial reporting and we have disclosed to theauditors and the Audit Committee deficiencies in the design or operation of such internalcontrols if any of which we are aware and the steps we have taken or propose to take torectify these deficiencies.

(d) We have indicated to the auditors and the Audit committee

(i) significant changes in internal control over financial reporting during the year;

(ii) significant changes in accounting policies during the year and that the same havebeen disclosed in the notes to the financial statements; and

(iii) instances of significant fraud of which we have become aware and the involvementtherein if any of the management or an employee having a significant role in thecompany’s internal control system over financial reporting.

By order of the Board
For LIFELINE DRUGS AND PHARMA LIMITED
Alok Kr. Behera
(DIN: 00272675)
May 27 2014 Managing Director

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard